Clinical Phase II Study of Pegylated Liposomal Doxorubicin as Second-Line Treatment in Disseminated Melanoma
- 1 December 2004
- journal article
- clinical trial
- Published by S. Karger AG in Oncology Research and Treatment
- Vol. 27 (6), 540-544
- https://doi.org/10.1159/000081335
Abstract
Stage IV melanoma has a poor prognosis with a median survival of 3-11 months from diagnosis of distant metastases. Response rates in first-line regimens range around 15-20%. Non-responders have a median survival around 6 months. Currently, no second-line treatment in advanced melanoma has been established. In a clinical phase II study we evaluated the efficacy of liposomal doxorubicin (Caelyx) in 30 patients (17 m, 13 f) with progressing metastatic melanoma who had failed a previous chemotherapy. Liposomal doxorubicin was given in an outpatient setting at a dose of 50 mg/m2 i.v. on d1, d22, d43 and d64, subsequently at 40 mg/m2 at d85 before first staging and in 4-week intervals thereafter. Treatment was very well tolerated with 100 cycles given in total. Response rate, survival time, time-to-progression and toxicity were assessed. Erythrodysesthesia was the most severe toxicity in 6% at CTC grade 3. Liposomal doxorubicin was of limited clinical efficacy with 21 patients progressing within the first 12 weeks. However, 7 patients were treated 3-9 months and were stable for >90 days, achieving 5 SD, 1 PR and 1 CR. Median survival after initiation of second-line treatment was 214 days (95% CI: 151-304 days) with 7 patients surviving >300 and 5 patients >400 days. Liposomal doxorubin as monotherapy is well tolerated but of limited clinical efficacy. Whether the survival benefit of a significant proportion of patients (20%) holds true in larger cohorts and whether the efficacy of liposomal doxorubicin can be improved by combinations without compromising the low toxicity profile needs further studies.Keywords
This publication has 14 references indexed in Scilit:
- Phase II study of pegylated liposomal doxorubicin in patients with metastatic malignant melanoma failing standard chemotherapy treatmentMelanoma Research, 2003
- Interferon Alfa Therapy for Malignant Melanoma: A Systematic Review of Randomized Controlled TrialsJournal of Clinical Oncology, 2002
- Is There a Standard for the Palliative Treatment of Melanoma?Oncology Research and Treatment, 2002
- Pegylated doxorubicin for primary cutaneous T-cell lymphoma: a report on ten patients with follow-upZeitschrift für Krebsforschung und Klinische Onkologie, 2001
- Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin.Archives of Dermatology, 2000
- Caelyx™ in malignant mesothelioma: A phase II EORTC studyAnnals of Oncology, 2000
- Chemosensitivity testing of human malignant melanoma. A retrospective analysis of clinical response and in vitro drug sensitivityCancer, 1994
- Prognostic factors in patients with metastatic malignant melanoma: A multivariate analysisCancer, 1993
- Pyridoxine Therapy for Palmar-Plantar Erythrodysesthesia Associated With TaxotereJNCI Journal of the National Cancer Institute, 1993
- Pyroxidine for the Palmar-Plantar Erythrodysesthesia SyndromeAnnals of Internal Medicine, 1989